Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis

被引：0
|
作者：
Lewiecki, E. Michael [1 ]
Dinavahi, Rajani V. [2 ]
Lazaretti-Castro, Marise [3 ]
Ebeling, Peter R. [4 ]
Adachi, J. [5 ]
Miyauchi, Akimitsu [6 ]
Gielen, Evelien [7 ]
Milmont, Cassandra E. [2 ]
Libanati, Cesar [8 ]
Grauer, Andreas [2 ]
机构：
[1] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Univ Fed Sao Paulo, Sao Paulo, Brazil
[4] Monash Univ, Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON, Canada
[6] Miyauchi Med Ctr, Osaka, Japan
[7] Univ Hosp Leuven, Leuven, Belgium
[8] UCB Pharma, Brussels, Belgium
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women
    Kanis, J. A.
    Harvey, N. C.
    Lorentzon, M.
    Liu, E.
    Vandenput, L.
    McCloskey, E. V.
    Johansson, H.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (01) : 165 - 171
  • [12] Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women
    J. A. Kanis
    N. C. Harvey
    M. Lorentzon
    E. Liu
    L. Vandenput
    E. V. McCloskey
    H. Johansson
    Osteoporosis International, 2021, 32 : 165 - 171
  • [13] Treatment of postmenopausal women with osteoporosis with PTH(1-84) for 36 months: treatment extension study
    Zanchetta, Jose R.
    Bogado, Cesar E.
    Cisari, Carlo
    Aslanidis, Spyros
    Greisen, Hanna
    Fox, John
    Lems, Willem
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) : 2627 - 2633
  • [14] Persistence At 12 Months With Denosumab (Prolia®) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study
    Silverman, Stuart L.
    Siris, Ethel
    Kendler, David L.
    Belazi, Dea
    Brown, Jacques P.
    Gold, Deborah T.
    Lewiecki, E. Michael
    Papaioannou, Alexandra
    Simonelli, Christine
    Ferreira, Irene
    Dakin, Paula
    Siddhanti, Suresh
    Stolshek, Bradley
    Recknor, Christopher
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S523 - S523
  • [15] Effects of Romosozumab in Postmenopausal Women With Osteoporosis After 2 and 12 Months Assessed by MicroCT on Iliac Crest Bone Biopsies.
    Roux, Jean-Paul
    Chavassieux, Pascale
    Chapurlat, Roland
    Portero-Muzy, Nathalie
    Garcia, Pedro
    Brown, Jacques P.
    Libanati, Cesar
    Boyce, Rogely
    Wang, Andrea
    Grauer, Andreas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S380 - S380
  • [16] Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
    Nakamura, Toshitaka
    Matsumoto, Toshio
    Sugimoto, Toshitsugu
    Hosoi, Takayuki
    Miki, Takami
    Gorai, Itsuo
    Yoshikawa, Hideki
    Tanaka, Yoshiya
    Tanaka, Sakae
    Sone, Teruki
    Nakano, Tetsuo
    Ito, Masako
    Matsui, Shigeyuki
    Yoneda, Toshiyuki
    Takami, Hideo
    Watanabe, Ko
    Osakabe, Taisuke
    Shiraki, Masataka
    Fukunaga, Masao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (07): : 2599 - 2607
  • [17] Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
    Lindsay, R
    Scheele, WH
    Neer, R
    Pohl, G
    Adami, S
    Mautalen, C
    Reginster, JY
    Stepan, JJ
    Myers, SL
    Mitlak, BH
    ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (18) : 2024 - 2030
  • [18] Evaluation of Invasive Oral Procedures and Events in Women With Postmenopausal Osteoporosis Treated With Denosumab: Results From the Pivotal Phase 3 Fracture Study Extension.
    Watts, Nelson B.
    Grbic, John T.
    McClung, Michael
    Papapoulos, Socrates
    Kendler, David
    Teglbjaerg, Christence S.
    O'Connor, Lawrence
    Wagman, Rachel B.
    Ng, Eric
    Daizadeh, Nadia S.
    Ho, Pei-Ran
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S112 - S112
  • [19] Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab. Results from the Pivotal Phase 3 Fracture Study Extension
    Watts, Nelson B.
    Grbic, John T.
    McClung, Michael
    Papapoulos, Socrates
    Kendler, David
    Teglbjaerg, Christence S.
    O'Connor, Lawrence
    Wagman, Rachel B.
    Ng, Eric
    Daizadeh, Nadia S.
    Ho, Pei-Ran
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S407 - S407
  • [20] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
    Saag, Kenneth
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul D.
    Grauer, Andreas
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345